Research programme: lung disorder biotherapeutics - Vectura/Comprehensive Pneumology Center

Drug Profile

Research programme: lung disorder biotherapeutics - Vectura/Comprehensive Pneumology Center

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Activaero GmbH; Comprehensive Pneumology Center
  • Developer Comprehensive Pneumology Center; Vectura
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Lung disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in Germany (Inhalation)
  • 13 Mar 2014 Activaero GmbH has been acquired by Vectura
  • 18 Jun 2013 Preclinical trials in Lung disorders in Germany (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top